Read the full article (PDF) >
This fall, the Supreme Court will hear argument in Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. relating to generic versions of Teva’s multiple sclerosis drug, Copaxone®. This case deserves close attention for its potential to affect interpretation and enforcement of patent rights, patent litigation strategies, and ultimately, patent value.
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.